TriSalus Life Sciences, Inc.
TLSI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $200,218 | $179,301 | $157,469 | $132,773 |
| - Cash | $22,687 | $26,490 | $13,000 | $8,525 |
| + Debt | $34,124 | $33,662 | $33,116 | $23,629 |
| Enterprise Value | $211,655 | $186,473 | $177,585 | $147,877 |
| Revenue | $11,566 | $11,213 | $9,167 | $8,261 |
| % Growth | 3.1% | 22.3% | 11% | – |
| Gross Profit | $9,660 | $9,411 | $7,672 | $7,045 |
| % Margin | 83.5% | 83.9% | 83.7% | 85.3% |
| EBITDA | -$9,183 | -$6,703 | -$8,989 | -$8,848 |
| % Margin | -79.4% | -59.8% | -98.1% | -107.1% |
| Net Income | -$10,811 | -$8,288 | -$10,375 | -$10,108 |
| % Margin | -93.5% | -73.9% | -113.2% | -122.4% |
| EPS Diluted | -0.96 | -0.27 | -0.39 | -0.41 |
| % Growth | -255.6% | 30.8% | 4.9% | – |
| Operating Cash Flow | -$3,709 | -$7,320 | -$4,499 | -$5,707 |
| Capital Expenditures | -$216 | $93 | -$754 | -$50 |
| Free Cash Flow | -$3,925 | -$7,227 | -$5,253 | -$5,757 |